ArticleClinical and experimental medicine2025
Polymyositis-like hypothyroid myopathy: diagnostic challenges and therapeutic outcomes in a case series.
Article in Clinical and experimental medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Myopathies in clinical care: a focus on treatable causes.Journal of neural transmission (Vienna, Austria : 1996) · 2026Review
- Unilateral lower limb cellulitis-like edema as an atypical cutaneous manifestation of antisynthetase syndrome: a case report and targeted literature review.Frontiers in medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hypothyroid myopathy, affecting 30-80% of hypothyroid patients, often mimics polymyositis, posing diagnostic challenges. This retrospective case series analyzed 10 patients (70% female, mean age 46.1 ± 10.3 years) with polymyositis-like hypothyroid myopathy. All presented with proximal muscle weakness, myalgia, and/or arthralgia, accompanied by elevated muscle enzymes (CK, CK-MB, LDH), liver dysfunction (70%), hyperlipidemia (70%), and serous effusions (pericardial effusion: 70%). Notably, all patients tested negative for myositis antibodies but exhibited thyroid dysfunction (↓fT3/fT4, ↑TSH) and positive thyroglobulin antibodies (100%). Muscle biopsies revealed degeneration and atrophy without necrosis or inflammation. After 3 months of thyroxine replacement therapy (100-150 µg/day), symptoms significantly improved (P < 0.05), with reductions in ALT, AST, CHOL, CK, CK-MB, and LDH (all P < 0.01), and normalization of fT3/fT4 levels. Muscle enzyme levels correlated negatively with fT3/fT4 (r
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.